We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-17.00 | -1.13% | 1,489.00 | 1,488.00 | 1,492.00 | 1,515.00 | 1,480.00 | 1,506.00 | 45,139 | 14:34:04 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.09B | 2M | 0.0148 | 1,003.38 | 2.01B |
Date | Subject | Author | Discuss |
---|---|---|---|
25/9/2017 07:22 | Rns out 🤡✌A | glenkaz | |
24/9/2017 13:06 | Cracking love ❤️ it 😱🔥 burning shorts 🤡👍 | glenkaz | |
15/9/2017 08:43 | Indivior files patent lawsuits | mjolnir69 | |
11/9/2017 15:52 | Interesting.Thanks Greg | steeplejack | |
11/9/2017 14:39 | The Morgan Stanley NY Conference webcast just finished. I was impressed by the content and upbeat tone. We will see what the market thinks. In my book, no new negatives and, if anything, bit more insight into the longer term potential. No additional product or NDA news obviously. Bup Monthly pricing decisions depend on the NDA labelling. I thought they sounded a bit more optimistic on the potential market for the lesser product the injectable RBP-7000, despite the existence of several established competitors . Questions on the postponed US Listing but the answer, to my understanding, was already known . Its all about the overhang of the long standing legacy litigation. Resolving these issues will leave the Co free to push the button on a US Listing. The US capital markets are seen as more receptive ( re valuations etc )to this type of Company than a more cautious Europe. We will see. | gregmorg | |
11/9/2017 13:01 | Mm,yes an interesting move although you and I know the institutional agenda is at times unfathomable and when least expected then turns on a sixpence/or even a gentle shake! Morgan Stanley Healthcare conference in NY today starting at 1.45pm, I believe. Not sure whether that will be a comforter but we shall see. A long way back to the £4 level but last week provided some welcome signs. Now, about the rest of the portfolio! | gregmorg | |
11/9/2017 12:04 | Scopia Capital have upped their interest by near a percentage point to over 12%. | steeplejack | |
10/9/2017 18:40 | Don't care taken profit 🤡✌A | glenkaz | |
08/9/2017 09:50 | I have been there and done it... in a former life Best of luck ... but in the end ... it does not work and statistics win out ie the market hxxps://vantagepoint | buywell3 | |
07/9/2017 19:23 | Nice one 🤡👌 | glenkaz | |
05/9/2017 17:32 | Nice small gains 🤡✌A | glenkaz | |
04/9/2017 17:53 | Dont think it will be long before others see the merits of their cash in the bank and assets. This is a quality company at a favourable price, that makes good money. | lyme regis1 | |
04/9/2017 09:21 | Back in 🤡👌 | glenkaz | |
04/9/2017 08:55 | time to buy...king of pharmaceutics:) | comedy | |
04/9/2017 08:38 | I recollect that what has come to pass was a known risk at the de-merger and that Indvior was something of one trick pony, which is still well above the relatively recent demerger price apportionment. | bscuit | |
04/9/2017 08:23 | Took 8% 🤡✌A | glenkaz |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions